MX2012007940A - Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. - Google Patents

Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.

Info

Publication number
MX2012007940A
MX2012007940A MX2012007940A MX2012007940A MX2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A
Authority
MX
Mexico
Prior art keywords
bevacizumab
mcrc
tumor tissue
combination therapies
tissue based
Prior art date
Application number
MX2012007940A
Other languages
English (en)
Inventor
Dorothee Foernzler
Paul Delmar
Stefan Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012007940A publication Critical patent/MX2012007940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para mejorar la superviviencia libre de progresión de un paciente que padece de cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC), por el tratamiento con bevacizumab (Avastin(r)) combinado con una posología de quimioterapia al determinar el nivel de expresión de uno o más de VEGFA, HER2 y neuropilina con relación a niveles control en pacientes diagnosticados con cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC) La presente invención adicionalmente proporciona los métodos para evaluar la sensibilidad o susceptibilidad de un paciente a bevacizumab (Avastin(r)) combinado con una posología de quimioterapia, al determinar el nivel de expresión de uno o más de VEGFA, HER2 y neuropilina con relación a niveles control en pacientes diagnosticados con cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC).
MX2012007940A 2010-01-19 2011-01-18 Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. MX2012007940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151109 2010-01-19
PCT/EP2011/050564 WO2011089101A1 (en) 2010-01-19 2011-01-18 Tumor tissue based biomarkers for bevacizumab combination therapies

Publications (1)

Publication Number Publication Date
MX2012007940A true MX2012007940A (es) 2012-08-03

Family

ID=43770611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007940A MX2012007940A (es) 2010-01-19 2011-01-18 Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.

Country Status (16)

Country Link
US (2) US20110182892A1 (es)
EP (2) EP2857040A1 (es)
JP (2) JP6057718B2 (es)
KR (1) KR101523419B1 (es)
CN (2) CN102711830A (es)
AU (1) AU2011208805A1 (es)
BR (1) BR112012016229A2 (es)
CA (2) CA2785774A1 (es)
HK (1) HK1208804A1 (es)
IL (1) IL220084A (es)
MX (1) MX2012007940A (es)
MY (1) MY172580A (es)
RU (1) RU2605282C2 (es)
SG (2) SG10201500479XA (es)
WO (1) WO2011089101A1 (es)
ZA (1) ZA201205014B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539460A (ja) * 2010-08-13 2013-10-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用療法のためのバイオマーカーとしてのニューロピリン
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
US9116159B2 (en) 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
US20170051062A1 (en) * 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
CN107076749B (zh) 2014-09-16 2020-12-29 瑞泽恩制药公司 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志
RU2017120388A (ru) * 2014-11-14 2018-12-14 Дженентек, Инк. Прогнозирование ответа на антагонист vegf
WO2016115149A1 (en) * 2015-01-12 2016-07-21 Aveo Pharmaceuticals, Inc. Neuropilin-1 as a serum based biomarker
CN104531714A (zh) * 2015-01-23 2015-04-22 香港中文大学深圳研究院 适用于植物表达体系的表达贝伐单抗的基因、重组载体及产贝伐单抗植物的构建方法及应用
CN105424682A (zh) * 2015-11-17 2016-03-23 苏州浩欧博生物医药有限公司 一种贝伐单抗试剂盒及其抗药抗体试剂盒
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
GR1009946B (el) * 2019-06-25 2021-03-04 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Οι συγκεντρωσεις της μπεβασιζουμαμπης σαν δεικτης στην ανταποκριση στη θεραπεια και στη συνολικη επιβιωση
RU2740361C1 (ru) * 2020-07-31 2021-01-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ органосохраняющего лечения операбельного рака прямой кишки

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275057A1 (en) * 2006-03-31 2009-11-05 Linke Steven P Diagnostic markers predictive of outcomes in colorectal cancer treatment and progression and methods of use thereof
EP2126126A2 (en) * 2007-01-18 2009-12-02 University Of Southern California Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
EP2109686A2 (en) * 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy

Also Published As

Publication number Publication date
HK1208804A1 (en) 2016-03-18
RU2605282C2 (ru) 2016-12-20
EP2857040A1 (en) 2015-04-08
JP2015178500A (ja) 2015-10-08
CA2785774A1 (en) 2011-07-18
IL220084A0 (en) 2012-09-24
BR112012016229A2 (pt) 2017-03-07
US20110182892A1 (en) 2011-07-28
KR20120123426A (ko) 2012-11-08
CN104474545A (zh) 2015-04-01
CN102711830A (zh) 2012-10-03
AU2011208805A1 (en) 2012-06-21
WO2011089101A1 (en) 2011-07-28
ZA201205014B (en) 2013-03-27
IL220084A (en) 2016-11-30
CA2891047A1 (en) 2011-07-18
JP6057718B2 (ja) 2017-01-11
MY172580A (en) 2019-12-04
US20140099302A1 (en) 2014-04-10
SG182520A1 (en) 2012-08-30
JP2013517258A (ja) 2013-05-16
EP2525821A1 (en) 2012-11-28
RU2012133472A (ru) 2014-02-27
SG10201500479XA (en) 2015-03-30
KR101523419B1 (ko) 2015-05-27

Similar Documents

Publication Publication Date Title
MX2012007940A (es) Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
AR089067A1 (es) Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
NZ592241A (en) Ykl-40 as a marker for gastrointestinal cancers
EA201200025A1 (ru) Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
NZ601348A (en) Methods for predicting response of triple-negative breast cancer to therapy
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX352373B (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
WO2012020123A3 (en) Neuropilin as a biomarker for bevacizumab combination therapies
WO2013132354A3 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
WO2016161153A3 (en) Prognostic and diagnostic methods for colorectal cancer
WO2010093450A3 (en) Pten phosphorylation-driven restistance to cancer treatment and altered prognosis
MX2014014821A (es) Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama.
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
WO2014066860A3 (en) Methods of prognosticating and treating cancer